Evicenter
Kisqali (ribociclib) in HR-positive HER2-negative advanced or metastatic breast cancer
Manufacturer
Novartis Pharmaceuticals Corporation
Prescribing information
Kisqali (opens in a new tab)
Questions
57
Last updated

All questions

Safety: Kisqali (ribociclib) in HR-positive HER2-negative advanced or metastatic breast cancer

14 questions · 4 sources

Side effects

What are the most common side effects of Kisqali in metastatic breast cancer?

Applies to Patients with HR-positive, HER2-negative advanced or metastatic breast cancer in pooled analyses of MONALEESA-2, MONALEESA-3, and MONALEESA-7

What are the side effects of Kisqali plus letrozole (MONALEESA-2)?

Applies to Postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer and no prior therapy for advanced disease, with letrozole (MONALEESA-2)

What are the side effects of Kisqali plus fulvestrant (MONALEESA-3)?

Applies to Postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer and no or one prior line of endocrine therapy for advanced disease, with fulvestrant (MONALEESA-3)

What are the side effects of Kisqali in premenopausal women (MONALEESA-7)?

Applies to Pre- and perimenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer and no prior endocrine therapy for advanced disease, with a nonsteroidal aromatase inhibitor and goserelin (MONALEESA-7)

What serious or fatal side effects occurred with Kisqali in MONALEESA trials?

Note: The three passages are from the MONALEESA-2 (with letrozole), MONALEESA-7 (with a nonsteroidal aromatase inhibitor and goserelin), and MONALEESA-3 (with fulvestrant) safety sections of the Prescribing Information, in that order.

How often did patients stop Kisqali for side effects in metastatic breast cancer trials?

Note: The three passages are from the MONALEESA-2, MONALEESA-7, and MONALEESA-3 safety sections of the Prescribing Information, in that order.

How often was the Kisqali dose reduced for side effects in MONALEESA trials?

Note: The three passages are from the MONALEESA-2, MONALEESA-7, and MONALEESA-3 safety sections of the Prescribing Information, in that order.

Warnings

Can Kisqali cause lung problems (ILD or pneumonitis)?

Note: The last passage is the dose adjustment guidance for ILD/pneumonitis on the dose adjustments page of the Kisqali HCP site.

Does Kisqali cause QT prolongation or heart rhythm problems?

How common is QT prolongation with Kisqali in each MONALEESA trial?

“Data are from a pooled analysis of 1054 premenopausal and postmenopausal patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (mBC) who were treated with KISQALI + an aromatase inhibitor (AI) or fulvestrant in the first- or second-line (1L/2L) across the MONALEESA-2, MONALEESA-3, and MONALEESA-7 trials.4 In the pooled analysis4: 1.4% of patients had a >500 ms postbaseline QTcF value 6% experienced a >60 ms increase from baseline in QTcF interval There were no reported cases of torsades de pointes In each MONALEESA trial: MONALEESA-2 (KISQALI + AI in 1L postmenopausal patients): <1% of patients had a >500 ms postbaseline QTcF value, and 3% experienced a >60 ms increase from baseline in QTcF interval. There was 1 (0.3%) sudden death in a patient with grade 3 hypokalemia and grade 2 QT prolongation1,4 MONALEESA-3 (KISQALI + fulvestrant in 1L/2L postmenopausal patients): 2% of patients had a >500 ms postbaseline QTcF value, and 7% experienced a >60 ms increase from baseline in QTcF interval. No cases of sudden death were reported2 MONALEESA-7 (KISQALI + AI in 1L premenopausal patients): The number of patients who had a >500 ms postbaseline QTcF value was not reached, and 7% experienced a >60 ms increase from baseline in QTcF interval. No cases of sudden death were reported3” (opens the source at this quote in a new tab)

On the page, select: How common is QT prolongation with KISQALI in metastatic breast cancer?

Can Kisqali cause liver problems?

Does Kisqali cause neutropenia (low white blood cell counts)?

Monitoring

What lab tests and monitoring are needed with Kisqali?

What tests are needed before starting Kisqali?